Skip to main content
    B

    BioCryst Pharmaceuticals Inc (BCRX)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $7.69
    +0.06 (+0.79%)

    Market Cap: $2.11B

    Last updated: Nov 06, 2026 at 4:20 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    68%(27/40)
    Avg Surprise
    +46.83%
    Streak
    7 Q

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$0.29
    Range$0.24 - $0.34
    2 analysts
    Revenue Consensus
    $210M
    Range$200M - $216M
    10 analysts
    Last 12 of 40 reported quarters and 1 upcoming estimate
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$0.29$0.24 - $0.34--2--
    Sep 26
    Reported Nov 4
    		$0.14$0.10$0.10 - $0.13+40.00%Beat2
    2
    0
    30d
    		-12.5%
    Jun 26
    Reported Aug 5
    		$0.30$0.14$0.08 - $0.39+114.29%Beat2
    0
    1
    30d
    		+650.0%
    Mar 26
    Reported May 6
    		$0.14$0.11$0.10 - $0.14+27.27%Beat4
    1
    0
    30d
    		+139900.0%
    Dec 25
    Reported Feb 26
    		$1.12$0.07$0.04 - $0.12+1500.00%Beat3
    1
    0
    30d
    		+961.5%
    Sep 25
    Reported Nov 3
    		$0.16$0.07$0.02 - $0.15+128.57%Beat4
    1
    0
    30d
    		+328.6%
    Jun 25
    Reported Aug 4
    		$0.04$0.03$0.00 - $0.10+33.33%Beat6
    1
    1
    30d
    		+166.7%
    Mar 25
    Reported May 5
    		$0.00N/A-+100.20%Beat5
    1
    2
    30d
    		+100.1%
    Dec 24
    Reported Feb 24
    		$-0.13$-0.06$-0.10 - $-0.01-115.23%Miss5
    1
    2
    30d
    		+53.6%
    Sep 24
    Reported Nov 4
    		$-0.07$-0.08$-0.09 - $-0.03+12.50%Beat9
    No revisions (30d)
    		+63.2%
    Jun 24
    Reported Aug 5
    		$-0.06N/A-+62.50%Beat11
    No revisions (30d)
    		+75.0%
    Mar 24
    Reported May 6
    		$-0.17$-0.23$-0.28 - $-0.14+26.09%Beat11
    No revisions (30d)
    		+39.3%
    Dec 23
    Reported Feb 26
    		$-0.28$-0.24$-0.38 - $-0.14-16.67%Miss11
    No revisions (30d)
    		+26.3%

    Key Metrics

    Valuation
    P/E Ratio4.52EV/EBITDAN/A
    Price/FCF5.37xFCF Yield18.61%
    Profitability
    Profit Margin-37.40%Operating Margin29.60%
    ROE-1925.00%ROIC24937.07%
    Financial Health
    Debt/Equity-1.00xInterest Coverage3.67x
    Current Ratio2.71xQuick Ratio2.64x
    Trading Statistics
    Beta0.51Avg Volume5.72M
    52-Week High$11.2252-Week Low$6.23

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$8.17
    SMA 20$8.06
    SMA 50$8.46
    SMA 200$8.78
    EMA 10$8.06
    EMA 20$8.13
    EMA 50$8.43
    EMA 200$8.73

    MACD

    Line: -0.11Signal: -0.11Hist: -0.00

    ADX

    ADX: 16.7+DI: 19.5-DI: 24.2

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down100.0
    PSAR$8.83

    Bollinger Bands

    Upper Band$8.65
    Lower Band$7.46
    %B Position1476%(Upper)
    Band Width0.19

    RSI (14-Day)

    Neutral
    40.8

    Momentum Oscillators

    Stoch %K29.9
    Stoch %D52.1
    Williams %R-79.1
    ROC (10d)0.5%
    Momentum0.04
    CCI (20d)-121.6
    MFI (14d)32.7

    Volatility Measures

    ATR (14d)$0.39(5.0%)
    StdDev (20d)0.30
    Hist Vol47.4%(High)

    Volume Flow

    VWAP$7.63
    OBV-133.8M
    AD Line-61.8M
    CMF (20d)-0.046

    Volume Metrics

    Avg Vol (20d)5.9M
    Vol Ratio0.9x
    VWMA (20d)$8.03

    Pivot Points

    R3$8.99
    R2$8.63
    R1$8.13
    Pivot Point$7.77
    S1$7.27
    S2$6.91
    S3$6.41

    Advanced Oscillators

    TSI-8.28
    Ultimate Osc43.8
    KST-26.17

    Financial Data

    QuarterSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total Revenue$180.29M$218.25M$156.41M$406.56M$159.40M$163.35M$145.53M$131.53M$117.08M$109.33M$92.76M$93.40M
    Cost of Revenue$1.57M$3.84M$5.38M$9.52M$2.19M$2.80M$4.57M$6.09M$3.21M$1.70M$1.26M$1.56M
    Gross Profit$178.72M$214.41M$151.04M$397.03M$157.21M$160.56M$140.97M$125.44M$113.87M$107.63M$91.50M$91.84M
    Operating Expenses$125.39M$115.94M$852.63M$136.65M$127.62M$130.77M$119.74M$129.95M$106.18M$98.87M$105.98M$134.51M
    R&D$58.21M$51.97M$758.08M$40.87M$44.60M$43.39M$37.27M$49.44M$41.08M$37.62M$46.49M$70.05M
    SG&A$67.17M$63.98M$94.55M$95.78M$83.01M$87.38M$82.47M$80.51M$65.10M$61.25M$59.49M$64.56M
    Operating Income$53.33M$98.47M$-701,598,000$260.38M$29.59M$29.79M$21.23M$-4,508,000$7.69M$8.76M$-14,488,000$-42,670,000
    Interest Income$3.10M$2.46M$2.03M$2.77M$2.27M$2.45M$3.02M$3.22M$3.69M$3.47M$3.73M$4.09M
    Interest Expense$21.18M$21.71M$19.78M$24.56M$22.40M$25.75M$23.49M$24.45M$24.83M$24.73M$24.51M$24.58M
    Income Before Tax$38.59M$79.47M$-720,808,000$248.02M$12.13M$6.49M$758,000$-25,991,000$-13,447,000$-12,502,000$-35,014,000$-63,162,000
    Income Tax Expense$669,000$1.08M$1.00M$2.17M$-769,000$1.40M$726,000$804,000$586,000$172,000$365,000$-1,431,000
    Net Income$37.92M$78.39M$-721,812,000$245.84M$12.90M$5.08M$32,000$-26,795,000$-14,033,000$-12,674,000$-35,379,000$-61,731,000
    EBITDA$55.67M$98.82M$-701,748,000$259.69M$32.27M$29.42M$20.72M$-6,423,000$6.47M$-3,261,000$2.08M$-96,535,000
    EBIT$56.67M$98.72M$-703,060,000$260.38M$32.26M$29.79M$21.23M$-4,508,000$7.69M$8.76M$-14,488,000$-42,670,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about BCRX

    Government Contracts

    Gov Obligations (TTM)
    $36032
    Gov Obligations / Revenue
    0.0%
    Obligations YoY
    100.1%
    Active Awards
    8
    New Awards (TTM)
    3
    Avg Remaining Term
    1.8 mo

    Top agency: Department of Veterans Affairs at 100.0% of trailing twelve month obligations across 1 agencies

    Recent Awards

    Award IDAgencyObligatedStart
    36C26026F0006Department of Veterans AffairsDepartment of Veterans Affairs$360000Oct 1, 2025
    36C26026F0294Department of Veterans AffairsDepartment of Veterans Affairs$151465May 19, 2026
    36C24926F0152Department of Veterans AffairsDepartment of Veterans Affairs$30293May 21, 2026

    Federal contract obligations are bookings recorded by the awarding agency, not recognized revenue. They can exceed 100% of revenue and can be negative when contracts are de-obligated. Source: USAspending.gov prime awards, data through Jul 31, 2026.

    BCRX Valuation and Fair Value

    P/E
    4.5x
    Forward P/E
    14.5x
    P/FCF
    5.4x
    PEG
    9.4x
    P/B
    -4.9x
    See GNG's fair value

    BCRX Profitability: Margins, ROIC and FCF

    Gross margin
    97.9%
    Operating margin
    29.6%
    Net margin
    -37.4%
    ROIC
    24937.1%
    ROE
    -1925.0%
    FCF margin
    38.0%
    FCF yield
    18.6%

    BCRX Competitors

    CompanyTicker
    Dynavax Technologies CorporationDVAX
    Biohaven Ltd.BHVN
    NeoGenomics IncNEO
    Prestige Brand Holdings IncPBH
    Schrodinger IncSDGR
    Avadel Pharmaceuticals PLCAVDL
    Vera Therapeutics IncVERA
    Select Medical HoldingsSEM

    Sector: Healthcare

    BCRX Analyst Ratings

    Consensus
    Buy
    Analysts
    11
    Strong Buy
    2
    Buy
    7
    Hold
    2
    Sell
    0
    Strong Sell
    0

    BCRX Bull Case vs Bear Case

    Bull case

    • BCRX earns a 24937.1% return on invested capital.
    • BCRX converts 38.0% of revenue into free cash flow.
    • BCRX beat EPS estimates in 87.5% of its last 8 reported quarters.

    Bear case

    • BCRX has a -37.4% net profit margin.

    BCRX Earnings: Beat Rate and Next Report

    Beat rate
    7 of 8 quarters (87.5%)
    Average surprise
    228.6%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $0.29

    BCRX Earnings Date

    BCRX reports Feb 24, 2027, after the close. The date is estimated.

    BCRX Earnings Call

    The latest BCRX earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    BCRX ETF Holders

    GNG tracks 14 ETFs that hold BCRX. The largest weights:

    1. abrdn Healthcare Investors (HQH), 1.74% of the fund
    2. State Street SPDR S&P Biotech ETF (XBI), 0.56% of the fund
    3. First Trust Small Cap Growth AlphaDEX Fund (FYC), 0.24% of the fund
    4. iShares Biotechnology ETF (IBB), 0.12% of the fund
    5. iShares Russell 2000 ETF (IWM), 0.12% of the fund
    Open the ETF Stock Exposure tool for BCRX

    See insider activity

    Frequently Asked Questions About BCRX

    When does BCRX report earnings?

    BioCryst Pharmaceuticals Inc (BCRX) is expected to report earnings on Feb 24, 2027.

    Does BCRX pay dividends?

    BioCryst Pharmaceuticals Inc (BCRX) does not currently pay a regular dividend.

    What is BCRX's P/E ratio?

    BioCryst Pharmaceuticals Inc has a price-to-earnings (P/E) ratio of 4.52.

    What is BCRX's market cap?

    BioCryst Pharmaceuticals Inc (BCRX) has a market capitalization of $2.11B with a current stock price of $7.69.

    Related stocks

    Sector: Healthcare

    All stocks starting with B

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In